Abstract
Polycystic kidney disease is a genetic or acquired disorder in which balloon-like structures called cysts which are filled with fluid are formed inside the kidneys. The most common type of PKD is autosomal dominant polycystic kidney disease (ADPKD). The major cause of ADPKD are found to be abnormalities in the genes, and these abnormalities are inherited within generations. Genetic mutations such as spontaneous mutations are observed in some cases of ADPKD. Other causes of ADPKD can be hypertension and proteinuria. ADPKD develops due to mutations in the genes PKD1 or PKD2. It is found that 85% of the ADPKD patients have mutated PKD1 and 15% of the ADPKD patients have mutated PKD2. It is the 4th common cause which results in End-Stage Renal Disease (ESRD). Different researches and studies are undergoing to find novel treatments for the diseases. There is a need to have a clear understanding of molecular and genetic pathogenesis of ADPKD to help build novel therapies. After the approval of Tolvaptan, an V2R antagonist, slow growth of cyst and less chances of kidney failure were observed in ADPKD patients. Some other therapies like mTOR pathways inhibitors, somatostatin therapies also help in halting the progression of disease. Complementary therapies such as ayurveda and homeopathy, yoga, acupuncture which can help prevent the progression and symptoms of ADPKD. More and more advancement of technologies, stem cell and nanoscience have emerged in finding solutions for renal replacement therapies and restoration of renal function.
Keywords: Autosomal dominant polycystic kidney disease (ADPKD), complementary therapies, stem cell and nanoscience.
References
- Bergmann C, Guay-Woodford L, Harris P C, Horie S et al. (2018). Polycystic Kidney Disease. Nat Rev Dis Primers. 4(1):50.
- Noël N, Rieu P. (2015). Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease. Nephrol Ther. 11 (4):213-25.1
- Rastogi A, Ameen K M et al. (2019). Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 15:1041-1052.
- Halvorson CR, Bremmer MS, Jacobs SC. (2010). Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis. 3:69-83.
- Vikrant S, Parashar (2017). Autosomal dominant polycystic kidney disease: Study of clinical characteristics in an indian population. Saudi J Kidney Dis Transpl. 28:115-24.
- Helal I, Li X. (2015). Treatment and Management of Autosomal Dominant Polycystic Kidney Disease. Brisbane (AU): Codon Publications. Chapter 3.
- Bastos AP, Onuchic LF. (2011). Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease. Braz J Med Biol Res. 44(7):606-17.
- Happe H, Peters D. (2014). Translational research in ADPKD: lessons from animal models. Nat Rev Nephrol. 10(10): 587-601.
- Hopp K, Ward CJ et al. (2012). Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 122(11): 4257-4273.
- Grantham JJ. (2014). Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol. 30(7):1053-62.
- Yu ASL, El-Ters M, Winklhofer FT. (2015). Clinical Trials in Autosomal Dominant Polycystic Kidney Disease. Brisbane (AU): Codon Publications. Chapter 6.
- Rangan GK, Tchan MC, Tong A, Wong TY, Nanikivell BJ. Recent advances in autosomal -dominant polycystic kidney disease. Internal Medicine J. 46(8):883-892.
- Torra R. (2019). Recent advances in the clinical management of autosomal dominant polycystic kidney disease. F1000Res. 8: F1000 Faculty Rev-116.
- Wüthrich RP, Kistler AD, Rodriguez D et al. (2015). Blood Pressure Control for Polycystic Kidney Disease. Brisbane (AU): Codon Publications. Chapter 5.
- Chapman AB, Stepniakowski, Rahbari-Oskoui F. (2010). Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 17(2):153-63.
- Tellman MW, Bahler CD, Shumate AM, Bacallao, Sundaram CP. (2015). Management of pain in autosomal dominant polycystic kidney disease and anatomy of renal intervention. J Urol. 193(5):1470-8.
- Sans-Atxer L, Joly D. (2018). Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 11: 41-51.
- Caroli A, Perico N et al. (2013). Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicenter trial. Lancet. 382(9903):1485-95.
- Rastogi A, Ameen KM et al. (2019). Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 15:1041-1052.
- Patel MV, Gupta SN, Patel NG. (2011). Effects of ayurveda treatment on 100 patients of chronic renal failure (other than diabetic nephropathy). Ayu. 32(4):483-486.
- Dong Z, Sun Y, Wei G, Li S, Zhao Z. (2019). A nucleoside/nucleobase-rich extract from cordyceps sinensis inhibits the epithelial-mesenchymal transition and protects against renal fibrosis in diabetic nephropathy. Molecules.24(22):4119.
- Shao G, Zhu S, Yang B. (2021). Applications of Herbal Medicine to treat Autosomal Dominant Polycystic Kidney Disease. Front. Pharmacol.12: 629848.
- Pandey RK, Tung VS, Kumar A, Yadav A. (2017). Effects of 6 months yoga program on renal functions and quality of life in patients suffering from chronic kidney disease. Int J Yoga. 10(1):3-8.
- Xiong W, He F, You R et al. (2018). Acupuncture application in chronic kidney disease and its potential mechanisms. The American Journal of Chinese Medicine. 46(6):1169-1185.
- Ciampi O, Bonandrini B, Derosas M, Conti S et al. (2019). Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. Sci Rep. 9(1):8001.
- Liu D, Cheng F, Pan S, Liu Z. (2020). Stem cells: a potential treatment option for kidney diseases. Stem Cell Res Ther. 249.
- Potts JW, Mousa SA. (2017). Recent advances in management of autosomal dominant polycystic kidney disease. American Journal of Health-System Pharmacy. 74(23):1959-1968.
- Soriano ML, Rodríguez-Benot A, Valcárcel M. (2018). Nanotechnological foundations of a “new” nephrology. Nefrología.38(4):362-372.T Khamphaya, P Pouyfung, S Kuraeiad, U Vattanasit and S Yimthiang. Current aspect of bisphenol a toxicology and its health effects. Trends Sci. 2021; 18, 408.
Corresponding Author
Ayushi Bisht
Dept of Clinical Research, Amity University Haryana
DOI: https://dx.doi.org/10.18535/jmscr/v11i7.07
